India, May 23 -- Boundless Bio (BOLD), a clinical-stage oncology company, Friday said it would reduce its workforce by about one-third as it streamlines its operations.
The company said it is discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial. It also plans to evaluate BBI-355 and BBI-825 as a combination therapy in the POTENTIATE clinical trial, targeting initiation in the second half of 2025.
"At Boundless, we're committed to delivering innovative therapies for patients with oncogene-amplified cancers through disciplined execution," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "By prioritizing the novel combination of BBI-355 and BBI-825, along with our exciting...